2013年国际抗癫痫该协会抗癫痫药使用指南
2022-04-26 00:41:28 来源: 合肥癫痫医院 咨询医生
he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查阅信源地址
- 2022-04-262013年国际抗癫痫该协会抗癫痫药使用指南
- 2022-04-21老年癫痫症状的饮食应注意什么
- 2022-04-13银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 2022-04-12第七届中澳亚太微创妇科论坛暨第三届全国第二代宫腔能源应用研讨会暨第二届基层医院妇女盆底修复重建培训班
- 2022-04-11癫痫治疗障碍仍难以克服
- 2022-04-07Cell J:对比研究揭示了子宫内膜异位症的另一种可能机制
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 第七届中澳亚太微创妇科论坛暨第三届全国第二代宫腔能源应用研讨会暨第二届基层医院妇女盆底修复重建培训班
- 疾病新知:毛囊性白癜风
- 癫痫治疗障碍仍难以克服
- Cell J:对比研究揭示了子宫内膜异位症的另一种可能机制
- 抗癫痫药物预防新发癫痫:任重而道远
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 长期用药治疗慢性疼痛或弊大于益
- FDA 批准银屑病新药 ixekizumab
- 你的输卵管还漂亮吗?
- 第一次同房失败,怎么治疗?
- 自身免疫病也可以免疫治疗
- 又痒又痛……银屑病的病因是什么?如何治愈?
- 半年无业绩 国药控股先后出让投资公司75%股份
- 前庭腺囊肿
- 第二届微创、超声介入学科发展及临床应用研讨会
- 癫痫猝死:凶手是谁?
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- 还会怀孕吗?
- 治疗鼻窦真菌感染
- 患者的饮食保健
- 扬子江药业评价信息:同日两品种获批上市!今年,共有86个品种的评价
- 体检发现钙化?我该怎么办?
- 惊厥性癫痫持续状态如何正确用药?最新共识告诉你
- 甲硝唑 VS 替硝唑,只是一字之差吗?
- 为什么身上有小白点 可能得了这种病?
- 治疗白癜风的阿普斯特临床数据
- 超声造影“揪出”隐藏在肝脏内的定时
- 昆明治疗癫痫病的分析方法有什么
- 中医无论如何怎么治疗癫痫病
- 癫痫病是什么症状及治疗法则
- 怎么才能早早的断定有癫痫病?
- 癫痫发作的呕吐及急救措施
- 郑州疗法癫痫病的医院哪家好
- 怎么于明治癫痫病最有效啊
- 小儿癫痫病有什么病因
- 治疗癫痫病比较好的方法有有哪些
- 怎么了解到癫痫病的症状与治疗
- 成人癫痫病因是什么呢
- 症状性癫痫治疗经费要多少钱